PMC:7274968 / 4080-4309
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
78 | 119-126 | Species | denotes | patient | Tax:9606 |
82 | 4-17 | Disease | denotes | breast cancer | MESH:D001943 |
83 | 30-38 | Disease | denotes | COVID-19 | MESH:C000657245 |
84 | 201-207 | Disease | denotes | tumors | MESH:D009369 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T7 | 4-10 | Body_part | denotes | breast | http://purl.org/sig/ont/fma/fma9601 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T3 | 4-10 | Body_part | denotes | breast | http://purl.obolibrary.org/obo/UBERON_0000310 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T20 | 4-17 | Disease | denotes | breast cancer | http://purl.obolibrary.org/obo/MONDO_0007254 |
T21 | 11-17 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T22 | 30-38 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T23 | 201-207 | Disease | denotes | tumors | http://purl.obolibrary.org/obo/MONDO_0005070 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T52 | 4-10 | http://purl.obolibrary.org/obo/UBERON_0000310 | denotes | breast |
T53 | 69-71 | http://purl.obolibrary.org/obo/CLO_0053733 | denotes | 11 |
T54 | 72-74 | http://purl.obolibrary.org/obo/CLO_0050507 | denotes | 22 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T12 | 4-17 | Phenotype | denotes | breast cancer | http://purl.obolibrary.org/obo/HP_0003002 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T35 | 0-229 | Sentence | denotes | For breast cancer, during the COVID-19 pandemic half of the centers (11/22, 50%) omitted radiotherapy boost unless the patient presented with significant risk factors of relapse (≤60 years, high-grade tumors, inadequate margins). |